Sandia LabNews

Battling COVID-19 with CRISPR

Sandia scientists race to find deployable antiviral countermeasure

digital rendering of broken DNA chain
BREAKING THE CHAIN — Sandia biochemist Joe Schoeniger and virologist Oscar Negrete are conducting research using CRISPR-based technology to genetically engineer a deployable antiviral countermeasure for COVID-19. Their goal is to create an antiviral that will be customizable to respond to many different viruses, including coronavirus. (Image by Loren Stacks)

Two Sandia researchers are using genetic resequencing tools to find a way to stop the COVID-19 pandemic in its tracks.

Biochemist Joe Schoeniger and virologist Oscar Negrete are working on genetically engineering a deployable antiviral countermeasure for COVID-19 using CRISPR-based technology.

“The goal is to find new ‘reloadable’ countermeasures for viral outbreaks that do not have to be re-invented every time,” Joe said. “CRISPR is a technology which allows us to address specific sequences of DNA and RNA, safely editing genes or controlling gene expression, to target viruses and improve the body’s ability to resist infection.”

Once their research is complete, the antiviral will be customizable to respond to many different viruses, including coronavirus.

“We are developing safe CRISPR-based technologies that send temporary reprogramming codes to your body that will inhibit virus infection,” Oscar said. “We’re also developing nanoparticle delivery systems to protect the CRISPR constructs until they get to the right cells and tissues to modulate the body’s response.”

This CRISPR-based research is funded by the Biological Technologies Office at the Defense Advanced Research Projects Agency.

Not just a health problem

“I think this current pandemic shows that we have a vulnerability to this and that this is more than a health problem. It is a national security problem,” Joe said. “Coronavirus was already on our radar. When the new strain called SARS-CoV-2 emerged and it was clear this was not a local problem in China, we started to pivot to that research pretty early. We’ve added on more institutional work since then.”

The team is conducting proof-of-concept trials now, after which other institutions involved in the research will conduct animal testing of the modified genes. Joe said the work will continue even if this outbreak is controlled.

“There’s a long tail that’s going to be around for a while,” he said. “Things can happen during that tail that we can’t know. We want to help reinforce that response to not only a new outbreak of COVID-19, but outbreaks of all kinds.”